Having established that LFPRLR SMO treatment did not affect TGF-β1 or IL-10 production by tumor Tregs, we used RNAseq analysis of tumor Tregs to gain some unbiased insight into which other secreted factors could possibly be responsible for the reduced ability of Tregs to promote epithelial to mesenchymal transition after LFPRLR SMO treatment. The gene discussed is TGFB1; the disease is neoplasm.